Research programme: anti-SARS inhaled therapeutics - Inhalon Biopharma
Latest Information Update: 22 Dec 2023
At a glance
- Originator Inhalon Biopharma
- Class Antibodies; Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Coronavirus infections